CagriSema vs Tirzepatide
An amylin/GLP-1 co-formulation against a dual incretin agonist.
The short answer: CagriSema pairs two separate molecules; tirzepatide is one molecule hitting two receptors.
CagriSema
Tirzepatide
Compound in Mounjaro® · Zepbound®Side by side
| Property | CagriSema | Tirzepatide |
|---|---|---|
| Research category | Metabolic Research | Metabolic Research |
| Presentation | 10mg vial | 2.5mg × 4 pens |
| Dosage options | 10mg · 20mg | 2.5mg × 4 pens · 5mg × 4 pens · 10mg × 4 pens · 15mg × 4 pens |
| Approved medicine using it | None — investigational | Mounjaro® · Zepbound® |
| Availability | In stock | In stock |
| Batch COA | Supplied with order | Supplied with order |
| From | €389.90 | €324.90 |
How they differ
Tirzepatide is a single peptide engineered to bind both GIP and GLP-1 receptors. CagriSema is a co-formulation of two distinct molecules: cagrilintide, a long-acting amylin analog, and semaglutide, a GLP-1 agonist.
The mechanistic difference is the amylin pathway. Amylin is co-secreted with insulin and acts on satiety through the area postrema — a route independent of the incretin system entirely. So CagriSema combines two unrelated satiety mechanisms, where tirzepatide combines two incretin ones.
Formulation matters for handling: a co-formulation means two active compounds in one vial, each with its own stability profile.
At the bench
A co-formulation means two active compounds sharing one vial, each with its own stability profile — storage has to suit the less tolerant of the two. Tirzepatide, being a single molecule, has one profile to respect.
What this comparison does not settle
Comparing a co-formulation to a single molecule compares a product to a compound. The ratio between cagrilintide and semaglutide is a formulation decision, and changing that ratio changes what is being compared.
Common questions
What is the difference between CagriSema and Tirzepatide?
CagriSema pairs two separate molecules; tirzepatide is one molecule hitting two receptors. An amylin/GLP-1 co-formulation against a dual incretin agonist.
Is CagriSema or Tirzepatide better?
Neither, and the question does not have a general answer. They are compared here on mechanism rather than merit. Comparing a co-formulation to a single molecule compares a product to a compound. The ratio between cagrilintide and semaglutide is a formulation decision, and changing that ratio changes what is being compared.
Which of the two has more published data?
Tirzepatide. It is the compound behind Mounjaro · Zepbound, so it carries a completed trial programme. CagriSema remains investigational.
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use. Brand names are trademarks of their respective owners and are referenced only to identify the active compound — no affiliation or equivalence is claimed.